More than 20 protein kinases are directly activated by 3-phosphoinositide-dependent kinase 1 (PDK1), which is a central component of the pathways that regulate cell growth, proliferation and survival. Despite the importance of PDK1 in cell signalling, highly selective PDK1 inhibitors have not been described. In this issue of the Biochemical Journal, Dario Alessi's group and their collaborators at GlaxoSmithKline report GSK2334470, a potent and selective PDK1 inhibitor. They show that this compound blocks the phosphorylation of known PDK1 substrates, but surprisingly find that the potency and kinetics of inhibition vary for different PDK1 targets. This substrate-specific inhibition has implications for the development of PDK1 inhibitors as drugs.
Skip Nav Destination
Article navigation
January 2011
- Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Commentary|
December 22 2010
For a PDK1 inhibitor, the substrate matters
Zachary A. Knight
Zachary A. Knight
1
1The Rockefeller University, 1230 York Avenue, New York, NY 10065, U.S.A.
1Email zknight@rockefeller.edu
Search for other works by this author on:
Biochem J (2011) 433 (2): e1–e2.
Article history
Received:
December 03 2010
Accepted:
December 07 2010
Connected Content
A commentary has been published:
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1
Citation
Zachary A. Knight; For a PDK1 inhibitor, the substrate matters. Biochem J 15 January 2011; 433 (2): e1–e2. doi: https://doi.org/10.1042/BJ20102038
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
101
Views
0
Citations

